A new treatment way of Hepatitis B with Allokin-alpha

Clinical studies have shown high efficiency of Allokin-alpha in the treatment of patients with acute Hepatitis B

The treatment with Allokin-alpha provides a favorable dynamics of clinical manifestations of AHB and promotes the recovery. The treated patients showed a clear trend towards a more rapid disappearance of intoxication symptoms and the duration of the temperature reaction reduced significantly.

The administration of Allokin-alpha reduced the period of clinical manifestations of Hepatitis B, it was especially evident on such symptom as jaundice and intoxication (the patients, who had been treating with Allokin-alpha did not need the infusion detoxification therapy).

Using Allokin-alpha in patients with acute Hepatitis B provided by positive dynamics of clinical manifestations (the reduction of intoxication terms and jaundiced period, promotion of recovery) and biochemical parameters of blood, where HBsAg eliminated rapidly from the blood, HBV DNA in comparison with the control group. The residual effects as prolonged convalescence or posthepatitic hepatomegaly rarely met in patients of the researched groups. Allokin-alpha was well tolerated and there were no toxic effects reported.

The researches allowed to establish the therapeutic efficiency of Allokin-alph n mild and moderate cases of acute Hepatitis B. The accurate results in reducing hyperbilirubinemia, elimination of HBsAg, the recovery time had been achieved by using the scheme with Allokin-alpha three times a week.

The use of Allokin-alpha in the treatment of patients with AHVB revealed a clear trend towards a more rapid disappearance of intoxication symptoms, a significant reduction in the duration of temperature reaction (p<0.001) and the period of jaundice (p>0.01) in comparison with the patients who had only basic therapy. During the treatment the rate of recession in levels of ALT and AST, alkaline phosphatase and gamma-glutamyl transpeptidase were higher in patients treated with alloferon. The recovery time of patients in test group was shorter than in the comparison group at all stages of observation. Moreover, the difference in time of patients' recovery treated with Allokin-Alpha - 10 mg 3 times a week, and patients in the comparison group was highly significant (p<0.001). Among the observed patients the formation of chronic Hepatitis B did not occur. At clinical observation it was found that the patients treated with alloferon, HBsAg was eliminated faster than in patients in the comparison group (p<0.05). In the period of convalescence there was observed a distinct tendency to accelerate elimination of HBV DNA from the blood of the patients treated with Allokin-alpha (alloferon).

Recommendations

Allokin-alpha is recommended for medical use for the treatment of patients with moderate form of acute Hepatitis B (jaundice). Allokin-Alpha is administered in the early stages of jaundiced period (up to the 7-th day) according to the scheme: 10 mg subcutaneously 3 times a week for 3 weeks. For the treatment course – 9 injection of 10 mg.

Ask your gynecologist if he (she) has an experience in treatment of human papillomavirus infection to the complete removal of human papilloma virus from the body?